Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Chemotherapy & Immunotherapy
Complex treatment of retinoblastoma
What the complex treatment of retinoblastoma entails, how eye-sparing modalities such as intra-arterial chemotherapy and plaque brachytherapy preserve sight, clinical evidence regarding tumour control, approximate costs in Turkey compared with the UK, US and Germany, step-by-step hospital procedures under anaesthesia, recovery timelines, potential risks, and guidance on selecting an accredited paediatric ocular oncology team.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Chemotherapy & Immunotherapy
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Complex Treatment of Retinoblastoma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Complex treatment of retinoblastoma in Turkey: eye salvage and multimodal protocols
The complex treatment of retinoblastoma refers to a coordinated, multimodality paediatric oncology protocol designed to eradicate malignant retinal tumours while prioritising the child's life, preserving the natural eye, and protecting useful vision. Retinoblastoma is the most common primary intraocular cancer of early childhood, originating in immature retinal cells called neuroblasts, almost always driven by genetic mutations in the RB1 tumour suppressor gene. In previous decades, the standard response was surgical eye removal (enucleation) or external beam radiotherapy. Today, specialised medical centres provide complex treatment of retinoblastoma in Turkey through advanced eye-sparing interventions that combine superselective intra-arterial chemotherapy, intravitreal medication delivery, plaque brachytherapy, and precise focal laser consolidation.
Because retinoblastoma develops in infants and young children under five years old, clinical management demands exceptional subspecialist expertise. For international families exploring care options abroad, comprehensive paediatric oncology treatments in Turkey unite paediatric oncologists, ocular oncologists, neuro-interventional radiologists, and paediatric anaesthetists within accredited tertiary hospitals to deliver personalized, organ-preserving protocols. This guide outlines how complex retinoblastoma protocols work, current clinical outcomes, realistic recovery expectations, comparative international costs, and how to select an experienced paediatric ocular oncology centre.
How does the complex treatment of retinoblastoma work?
The biological objective of complex treatment of retinoblastoma is to destroy malignant neuroblasts while sparing normal retinal architecture and surrounding intracranial structures. Rather than relying on a single treatment, clinicians employ a multimodal ladder tailored to the size, location, and genetic profile of the tumour:
- Superselective intra-arterial chemotherapy (IAC): Under general anaesthesia, a neuro-interventionalist threads a microcatheter through the femoral artery in the groin, navigating through the aorta and internal carotid artery to the ostium of the ophthalmic artery. Concentrated doses of melphalan, topotecan, or carboplatin are infused directly into the blood supply of the eye over 30 minutes, concentrating the medication in the tumour while reducing systemic exposure.
- Intravitreal chemotherapy: Micro-injections of melphalan or topotecan are delivered directly into the vitreous chamber using ultra-fine needles to eradicate free-floating vitreous seeds, accompanied by cryotherapy at the injection site to prevent tumour cells from seeding outside the eye.
- Focal consolidation therapies: Transpupillary thermotherapy (TTT), argon laser photocoagulation, and transscleral cryotherapy deliver concentrated heat or extreme cold to destroy small primary tumours and tumour blood vessels.
- Plaque brachytherapy: A custom titanium or gold radioactive plaque carrying iodine-125 or ruthenium-106 seeds is sutured temporarily to the outer sclera over the tumour base, providing targeted local radiation.
- Systemic chemoreduction: Intravenous chemotherapy protocols circulate through the entire body, essential when bilateral disease, germline mutations, or high-risk systemic features are present.
Does complex treatment of retinoblastoma actually work? Survival and eye-salvage outcomes
Yes. Contemporary international clinical literature demonstrates that multimodal retinoblastoma protocols achieve overall patient survival rates exceeding 95% in non-metastatic disease when treated in dedicated tertiary oncology centres. The clinical definition of success follows a strict hierarchy: saving the child's life, followed by salvaging the eye (globe preservation), and finally conserving visual acuity.
Eye-salvage outcomes depend directly on the stage of the disease at diagnosis, classified using the International Intraocular Retinoblastoma Classification (IIRC):
- Groups A, B and C (Early to moderate): Primary focal therapy and intra-arterial chemotherapy achieve eye preservation rates exceeding 90% to 95%, frequently maintaining functional vision.
- Group D (Advanced intraocular disease): Characterised by subretinal or vitreous seeds. Historically, these eyes were almost universally removed; however, modern intra-arterial chemotherapy protocols achieve eye salvage in 60% to 80% of Group D cases.
- Group E (Very advanced disease): Massive tumours filling more than half the eye, neovascular glaucoma, or tumours touching the lens. In Group E cases, primary enucleation remains the safest international standard of care to eliminate the risk of life-threatening extraocular dissemination.
While multimodal protocols have revolutionised globe salvage, no ethical hospital guarantees 100% eye preservation. If tumours prove resistant to multiple chemotherapy lines or if complications arise, secondary enucleation may be necessary to safeguard the child's life.
Complex treatment of retinoblastoma cost in Turkey compared with the UK, US and Germany
The overall complex treatment of retinoblastoma cost depends on the number of intra-arterial chemotherapy cycles required, the need for repeated examinations under anaesthesia (EUA), and whether adjuvant treatments such as plaque brachytherapy or prosthetic reconstruction are involved. The table below outlines broad approximate cost ranges for complete multi-cycle care programmes across major medical destinations.
| Country | Approximate cost range |
|---|---|
| Turkey | €8,000 – €28,000 |
| United Kingdom | €25,000 – €75,000 |
| United States | €45,000 – €140,000 |
| Germany | €22,000 – €65,000 |
Several clinical variables influence the final complex treatment of retinoblastoma price:
- Number of IAC cycles: Most children require between two and four intra-arterial chemotherapy sessions spaced three to four weeks apart.
- Biplane angiography and neuro-interventional suite fees: Superselective arterial catheterisation requires advanced catheterisation suites and specialized micro-catheters designed for paediatric vessels.
- Examinations under anaesthesia (EUA): Serial RetCam high-resolution digital imaging, tonometry, and ultrasonography performed under general anaesthesia before each therapeutic step.
- Genetic sequencing: Comprehensive testing for germline RB1 mutations to identify hereditary risks and guide sibling screening.
In Turkey, comprehensive international patient packages generally cover pre-procedure paediatric assessments, interventional radiology suite costs, chemotherapeutic medications, paediatric anaesthesiology, hospital ward accommodation, follow-up EUAs, and airport transfers.
Treatment modalities: intra-arterial chemotherapy, plaque brachytherapy and enucleation
Paediatric ocular oncologists select specific therapeutic modalities based on tumour staging, vitreous seeding, and the child's systemic genetic risk. The table below compares the primary modalities utilised within modern treatment pathways.
| Method | Best suited to | Typical limits |
|---|---|---|
| Intra-arterial chemotherapy (IAC) | Advanced unilateral or bilateral tumours (Group B to D) seeking eye salvage | Requires specialised neuro-interventional catheterisation; transient eyelid oedema |
| Plaque brachytherapy | Solitary medium-sized intraocular tumours or localised peripheral recurrences | Limited to tumours under 8–10 mm thickness; requires two surgical procedures |
| Focal consolidation (laser / cryo) | Small primary tumours (Group A) or small residual seeds after chemotherapy | Cannot penetrate thick tumours; produces localised retinal scarring |
| Enucleation (surgical eye removal) | Very advanced tumours (Group E), diffuse optic nerve risk, or non-seeing painful eyes | Permanent loss of the natural eye; requires orbital implant and ocular prosthesis |
In advanced clinical oncology, multimodal therapy often bridges systemic and local therapies. While systemic chemotherapy distributes medications throughout the body to control bilateral tumours or reduce metastasis risk, local arterial delivery targets the eye directly. In selected clinical research settings, researchers are evaluating early-stage immunotherapy concepts, while emerging targeted therapy protocols explore molecular pathways linked to cell cycle dysregulation in neuroblasts.
Who is a suitable candidate for eye-sparing retinoblastoma protocols?
Determining whether a child is a candidate for eye salvage protocols requires detailed staging by a multidisciplinary team. Clinical decisions balance tumour eradication against the vital priority of saving the child's life.
Favourable candidates for eye salvage
- Group A, B, or C intraocular tumours: Small to medium tumours confined to the retina without extensive vitreous or subretinal fluid dispersion.
- Group D tumours with intact ocular anatomy: Advanced intraocular tumours where the retina remains partially attached, media is clear, and the optic nerve is unaffected.
- Bilateral retinoblastoma: Children with tumours in both eyes, where aggressive eye-sparing protocols are prioritised to preserve at least partial visual function in one or both eyes.
- Stable physiological health: Children capable of undergoing repeated brief general anaesthesia for angiography and serial examinations.
Situations where primary enucleation is indicated
- Group E disease with anterior segment invasion: Tumour involvement of the iris, ciliary body, or anterior chamber, which elevates metastatic dissemination risks.
- Suspected extraocular or optic nerve invasion: High-resolution MRI evidence demonstrating tumour extension past the lamina cribrosa or into the orbital tissue.
- Secondary neovascular glaucoma or phthisis: A blind, chronically painful eye caused by tumour-induced vascular proliferation.
Step-by-step procedure: examinations under anaesthesia and targeted therapy delivery
Undergoing complex retinoblastoma treatment involves structured, multidisciplinary phases to guarantee absolute precision and patient safety throughout every intervention:
- Step 1: Examination under anaesthesia (EUA): Because young children cannot remain still for detailed eye exams, every assessment occurs under general anaesthesia. The ocular oncologist performs indirect ophthalmoscopy, captures 360-degree digital fundus photographs with a RetCam, measures intraocular pressure, and performs high-frequency B-scan ultrasonography.
- Step 2: Contrast-enhanced MRI: High-field 3T magnetic resonance imaging of the orbits and brain assesses tumour volume, checks for optic nerve infiltration, and rules out trilateral retinoblastoma (pineal gland involvement).
- Step 3: Superselective microcatheter navigation: In an interventional neuroradiology suite, a specialist introduces a French 3 or 4 paediatric sheath into the femoral artery in the groin. Under real-time fluoroscopic guidance, a microcatheter is navigated up to the origin of the ophthalmic artery.
- Step 4: Pulsed drug infusion: Chemotherapeutic agents (melphalan, topotecan, or carboplatin) are infused in a slow, pulsatile manner over 30 minutes. Intravenous heparin prevents clotting in the small microcatheter during the procedure.
- Step 5: Immediate focal consolidation and recovery: Following catheter removal and femoral haemostasis, the ocular oncologist may apply laser photocoagulation or cryotherapy directly to remaining active tumor edges. The child is gently awakened and monitored in a dedicated paediatric recovery unit.
Treatment results and monitoring: what clinical scans and fundus photographs show
Unlike surgical or aesthetic procedures where results are visible externally, retinoblastoma outcomes are evaluated through serial fundus photography and cross-sectional imaging under anaesthesia. Paediatric oncologists observe distinct patterns of tumour regression:
- Type 1 regression (Calcified): The tumour transforms into a chalky, calcified mass resembling cottage cheese, indicating complete non-viable tumour cell death.
- Type 2 regression (Non-calcified): The lesion shrinks into a translucent, grey, fish-flesh scar tissue without active vascular supply.
- Type 3 regression (Combined): A hybrid pattern displaying both calcified core areas and peripheral non-calcified fibrotic scar tissue.
- Type 4 regression (Atrophic flat scar): Complete flat chorioretinal scarring with surrounding pigmentary changes, typical after successful focal laser consolidation.
What images and photographs cannot predict is absolute visual acuity. If tumours were located away from the fovea (the central point of sharp vision), children often retain excellent visual acuity. Conversely, tumours that originated directly in the macula or resulted in total retinal detachment will result in reduced central vision even after the cancer is completely cured. Regular EUAs continue every three to six weeks during active management to ensure no new seedings or tumor recurrences arise.
Recovery timeline, hospital stays and travelling to Turkey
Managing complex treatment of retinoblastoma recovery requires understanding both the immediate post-procedure period and the recurring cycle schedule. Overall physical recovery from each individual treatment session is relatively rapid for paediatric patients.
- Immediate post-procedure (Days 1–2): Children spend several hours resting quietly after femoral catheterisation to prevent haematoma at the groin puncture site. Mild nausea or grogginess from anaesthesia typically subsides within 12 to 24 hours. Most patients are discharged from the hospital after one overnight stay.
- Short-term recovery (Days 3–7): Some children develop mild eyelid oedema (swelling) or temporary redness around the eye or forehead on the treated side following intra-arterial chemotherapy. This resolves spontaneously within three to seven days.
- Systemic blood count nadir (Days 10–14): While intra-arterial delivery significantly limits systemic toxicity compared to intravenous chemotherapy, mild bone marrow suppression can occur. Blood tests monitor white blood cell and platelet counts.
For international families, each treatment cycle generally requires a stay in Turkey of seven to ten days. This timeframe allows for admission, pre-procedure EUA, imaging, intra-arterial chemotherapy, overnight observation, and a follow-up assessment before travelling. Flying home is safe once the paediatrician confirms normal vital signs and femoral healing. Sessions are repeated every three to four weeks, with most protocols spanning three to four cycles.
Risks and complications of retinoblastoma therapies
Every oncology intervention carries potential risks that must be carefully managed by specialized teams. Paediatric ophthalmic oncology guidance from organisations such as the British Ophthalmic Oncology Group (BOOG), the American Academy of Ophthalmology (AAO), and the International Society of Genetic Eye Diseases and Retinoblastoma (ISGEDR) emphasizes the following primary risks:
- Local ocular complications: Intra-arterial chemotherapy can induce transient eyelid ptosis (drooping), eyelash loss, vitreous haemorrhage, or sectoral iris atrophy. In rare instances (estimated at less than 5%), arterial spasm or vascular thrombosis may cause branch or central retinal artery occlusion, which permanently limits visual recovery.
- Retinal detachment: Large collapsing tumours can produce exudative or rhegmatogenous retinal detachments, which frequently reattach as tumour fluid reabsorbs but may require secondary vitrectomy or scleral buckling.
- Radiation-associated side effects: Plaque brachytherapy can cause radiation retinopathy, optic neuropathy, or cataract formation months or years after treatment, especially when tumours lie close to the optic disc.
- Systemic and anaesthetic risks: Repeated general anaesthesia carries respiratory and cardiovascular risks in infants. Minor systemic drug absorption can cause temporary neutropenia, requiring vigilance against fever and infection.
- Risk of secondary malignancies: Children with germline RB1 mutations face a lifelong risk of secondary cancers (such as osteosarcoma). Modern protocols strictly avoid external beam radiation to minimise this genetic vulnerability.
How to choose a paediatric ocular oncology centre in Turkey and red flags
Retinoblastoma is a delicate condition requiring specialised institutional infrastructure. When selecting a centre for complex treatment of retinoblastoma in Turkey, parents should verify specific clinical benchmarks:
- Dedicated ocular oncology multidisciplinary team: Care must be directed by a verified ocular oncologist working hand-in-hand with paediatric oncologists and experienced interventional neuroradiologists.
- Paediatric intensive care unit (PICU): The hospital must have an accredited on-site paediatric intensive care unit and full-time paediatric anaesthesiology coverage.
- Advanced catheterisation technology: Interventional suites must feature biplane flat-panel angiography capable of superselective micro-catheterisation in infants.
- Access to advanced diagnostics: On-site high-resolution RetCam digital imaging, 3T MRI, paediatric ultrasound, and molecular genetic testing laboratories.
Red flags to watch for include clinics that promise guaranteed eye salvage or perfect vision restoration without reviewing scans, facilities lacking dedicated paediatric subspecialists, or coordinators who pressure families to commit before receiving an official multidisciplinary tumour board review. To learn how we coordinate paediatric oncology referrals, read how our process works.
Questions to ask the medical team
- Has our child's case been evaluated by a multidisciplinary paediatric ocular oncology board?
- What is the clinical stage and IIRC group of the tumour in each affected eye?
- What are the realistic prospects for eye salvage versus primary enucleation?
- How many paediatric intra-arterial chemotherapy procedures does the neuro-interventionalist perform annually?
- What emergency protocol is in place if our child develops a fever or severe eye swelling after discharge?
- How will follow-up RetCam images and medical reports be shared with our ophthalmologist back home?
You can share your child's medical records, ultrasound reports, and MRI scans through our free quote page for an in-depth review by an accredited paediatric ocular oncology team.
Conditions treated with Complex Treatment of Retinoblastoma
Hospitals with Oncology in Turkey
Frequently asked questions
The complex treatment of retinoblastoma is a multimodal paediatric oncology protocol designed to eradicate intraocular tumours, save the child's life, and preserve the eye and vision whenever possible. It combines targeted intra-arterial chemotherapy, intravitreal injections, focal therapies like laser photocoagulation or cryotherapy, plaque brachytherapy, and enucleation for advanced cases where salvage is unsafe.
Yes. When treated in specialised tertiary centres, retinoblastoma achieves overall survival rates exceeding 95%. Eye-salvage rates exceed 90% for early to moderate tumours (Groups A to C) and reach 60% to 80% for advanced Group D tumours using modern intra-arterial chemotherapy. However, very advanced Group E tumours with high metastatic risk often require enucleation to ensure survival.
In Turkey, the complex treatment of retinoblastoma typically ranges between €8,000 and €28,000, depending on the number of intra-arterial chemotherapy cycles, examinations under anaesthesia, and whether focal therapies or surgical interventions are required. This compares with €25,000 to €75,000 in the UK and upwards of €45,000 to €140,000 in the United States.
Treatment outcomes are evaluated through serial RetCam fundus imaging rather than external cosmetic appearance. Successful therapy shows progressive tumour regression into calcified or flat scar tissue, resolution of retinal detachment, and disappearance of vitreous seedings. Clinicians track these changes under anaesthesia every three to four weeks to verify that no active malignant tissue remains.
Intra-arterial chemotherapy delivers concentrated cytotoxic drugs directly into the ophthalmic artery, aiming to shrink tumours and preserve the natural eye and vision. Enucleation is the surgical removal of the eyeball, reserved for extensive tumours that have destroyed the eye or carry severe risk of spreading beyond the globe, prioritising child survival.
All diagnostic examinations, laser therapies, catheterisations, and surgeries are performed under paediatric general anaesthesia, ensuring the child feels no pain or distress during procedures. Mild post-procedural discomfort, such as grogginess, minor eyelid swelling, or forehead bruising, is typically managed with mild paediatric analgesics and resolves within two to three days.
Active treatment generally spans three to six months. Intra-arterial chemotherapy is administered in cycles every three to four weeks, usually requiring two to four cycles alongside concurrent focal laser or cryotherapy. Following active therapy, long-term surveillance with examinations under anaesthesia continues every several weeks to months until the child reaches age four or five.
Potential risks depend on the modality used. Intra-arterial chemotherapy can cause transient eyelid swelling, forehead redness, temporary low blood cell counts, or rarely arterial spasm and retinal vascular occlusion. Plaque brachytherapy carries risks of radiation retinopathy or cataracts. Severe systemic infections or secondary malignancies are minimised by avoiding external beam radiation.
Following an intra-arterial chemotherapy session or focal consolidation, children usually recover within 24 to 48 hours. Grogginess from anaesthesia clears by the next morning, and the small puncture mark in the groin heals rapidly. Parents monitor for fever or unusual eye discharge, with most children resuming normal eating, play, and daily activities almost immediately.
For each intra-arterial chemotherapy cycle, international families typically remain in Turkey for seven to ten days. This window covers pre-procedure examinations under anaesthesia, high-resolution imaging, catheter infusion, hospital observation, and a follow-up assessment before flying home. Some families choose to stay in Turkey between cycles to avoid frequent international flights.
Patient stories